Dimos, J. T., K. T. Rodolfa, K. K. Niakan, L. M. Weisenthal, H. Mitsumoto, W. Chung, G. F. Croft, G. Saphier, R. Leibel, R. Goland, H. Wichterle, C. E. Henderson, and K. Eggan. 2008. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893):1218-1221.
Dölen, G., E. Osterweil, B. S. Rao, G. B. Smith, B. D. Auerbach, S. Chattarji, and M. F. Bear. 2007. Correction of fragile X syndrome in mice. Neuron 56(6):955-962.
Drevets, W. C., J. L. Price, J. R. Simpson, Jr., R. D. Todd, T. Reich, M. Vannier, and M. E. Raichle. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386(6627):824-827.
Drevets, W. C., J. Savitz, and M. Trimble. 2008. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13(8):663-681.
Duff, K., and F. Suleman. 2004. Transgenic mouse models of Alzheimer’s disease: How useful have they been for therapeutic development? Brief Funct Genomic Proteomic 3(1):47-59.
Duman, R. S., and G. K. Aghajanian. 2012. Synaptic dysfunction in depression: Potential therapeutic targets. Science 338(6103):68-72.
Duman, R. S., N. Li, R. J. Liu, V. Duric, and G. Aghajanian. 2012. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacol 62(1):35-41.
Egan, M. F., R. E. Straub, T. E. Goldberg, I. Yakub, J. H. Callicott, A. R. Hariri, V. S. Mattay, A. Bertolino, T. M. Hyde, C. Shannon-Weickert, M. Akil, J. Crook, R. K. Vakkalanka, R. Balkissoon, R. A. Gibbs, J. E. Kleinman, and D. R. Weinberger. 2004. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. P Natl Acad Sci USA 101(34):12604-12609.
Epi4K Consortium. 2012. Epi4K: Gene discovery in 4,000 genomes. Epilepsia 53(8):1457-1467.
European Commission. 2010. Sixth report on the statistics on the number of animals used for experimental and other scientific purposes in the Member States of the European Union. Brussels, Belgium: European Commission. http://ec.europa.eu/environment/chemicals/lab_animals/reports_en.htm (accessed July 2, 2013).
FDA (U.S. Food and Drug Administration). 2005a. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf (accessed April 10, 2013).
FDA. 2005b. Guidance for industry, investigators, and reviewers: Exploratory IND studies. http://www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM0708933.pdf (accessed April 10, 2013).